State Street SPDR S&P Pharmaceuticals ETF
XPH
81 hedge funds and large institutions have $127M invested in State Street SPDR S&P Pharmaceuticals ETF in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
1% more funds holding
Funds holding: 80 → 81 (+1)
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
3.58% less ownership
Funds ownership: 51.23% → 47.65% (-3.6%)
11% less capital invested
Capital invested by funds: $143M → $127M (-$16.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.5M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.19M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$777K |
| 4 |
LPL Financial
San Diego,
California
|
+$335K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$323K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$11.4M |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$1.54M |
| 3 |
CF
Centaurus Financial
Anaheim,
California
|
-$1.17M |
| 4 |
Morgan Stanley
New York
|
-$910K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$780K |
XPH Hedge Fund Activity: Q1 2021 in Review
81 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2021, worth a combined $127M — down 11% from $143M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new XPH positions and 5 closed out — a net gain of 3 holders — while 22 added to existing stakes and 22 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $1.5M. The largest seller was JP Morgan Chase, cutting an estimated $11.4M.
- 81 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2021, up from 80 in Q4 2020.
- Funds reported $127M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2021, down 11% quarter-over-quarter.
- 8 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2021 and 5 closed out, a net change of +3 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2021 was Goldman Sachs, an estimated $1.5M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2021 was JP Morgan Chase, an estimated $11.4M sold.
Based on aggregated 13F filings for Q1 2021.